valve

Trombosis y riesgo de sangrado

WOEST 2 | Dual Versus Triple Antithrombotic Scheme in the Real World.

The WOEST study found a significant reduction in bleeding complications post PCI with oral anticoagulation indication (OAC) when treating patients with dual antiplatelet therapy (DAPT) vs. the triple antithrombotic scheme. Several randomized studies have shown these results. At present, the guidelines recommend using the triple antithrombotic scheme in patients according to ischemic and bleeding risk.&nbsp;<a href="https://solaci.org/en/2022/04/22/woest-2-dual-versus-triple-antithrombotic-scheme-in-the-real-world-antiplatelet-therapy-anticoagulation-scheme/" title="Read more" >...</a>

ACC 2022

ACC 2022 | FLAVOUR Study: FFR and IVUS in Intermediate Coronary Lesions

FLAVOUR was a prospective randomized non-inferiority study in patients with intermediate coronary lesions (40%-70%) that compared two imaging modalities: IVUS (intravascular imaging) and FFR (fractional flow reserve).&nbsp; According to this research—presented at ACC 2022—, FFR-guided angioplasty was non-inferior to IVUS-guided angioplasty at 2 years of follow-up. Furthermore, using FFR-based imaging led to fewer stent implantations.<a href="https://solaci.org/en/2022/04/13/acc-2022-flavour-study-ffr-and-ivus-in-intermediate-coronary-lesions/" title="Read more" >...</a>

ACC 2022

ACC 2022 | ADAPT-TAVR: Endoxaban Is Not Superior to DAPT After TAVR

DAPT-TAVR is a randomized trial that tested endoxaban in patients with no indication for anticoagulation who underwent successful transcatheter aortic valve replacement (TAVR) for symptomatic severe aortic stenosis. This study included 229&nbsp;patients whose mean age was 80&nbsp;years; 42% of them were male. Patients were randomized to either endoxaban 60&nbsp;mg or 30&nbsp;mg every 24 h or<a href="https://solaci.org/en/2022/04/13/acc-2022-adapt-tavr-endoxaban-is-not-superior-to-dapt-after-tavr/" title="Read more" >...</a>

estos son los artículos más leídos sobre tavi

Same-Day Discharger After TAVR: Are We There Yet?

Same-day discharge (SDD) has been shown to be effective in angioplasties and some peripheral procedures, but the pandemic—because of the burden it caused on the healthcare system—has forced the optimization of hospitalization times for other pathologies and procedures. This strategy is yet to be tested in transcatheter aortic valve replacement (TAVR) due to the possible<a href="https://solaci.org/en/2022/04/01/same-day-discharger-after-tavr-are-we-there-yet/" title="Read more" >...</a>

Ticagrelor Monotherapy after 3 Months: Is the Current Strategy Worth Changing?

Dual antiplatelet therapy (DAPT) after PCI with DES has shown noticeable reduction of thrombotic events, especially in acute coronary syndromes (ACS). However, this therapy encompasses increased bleeding, especially in elderly patients increasingly undergoing percutaneous intervention. Even though most bleeding events might not be fatal (many of them are mostly digestive) they do involve higher hospitalization<a href="https://solaci.org/en/2022/03/21/ticagrelor-monotherapy-after-3-months-is-the-current-strategy-worth-changing/" title="Read more" >...</a>

Webinar SOLACI-Medtronic: Casos imposibles: Revisión de casos complejos y controversiales en TAVI

Webinar SOLACI – Medtronic | Impossible Cases! Review of Complex and Controversial TAVR Cases

We invite the entire Latin American community to analyze challenging TAVR cases together with a panel of Latin American experts. We will be looking at vascular access sites, aortic anatomy, potential coronary compromise, Valve-in-Valve, and more!&nbsp; Date: March 24, 2022, at 07.30 PM (Argentinian/ Brazil time; UTC-3). The event will feature renowned experts from across<a href="https://solaci.org/en/2022/03/21/webinar-solaci-medtronic-impossible-cases-review-of-complex-and-controversial-tavr-cases/" title="Read more" >...</a>

La FDA aprueba el ticagrelor en pacientes de alto riesgo como prevención primaria

Abbreviated DAPT in ACS: The End of Clopidogrel Monotherapy?

Compared with patients with chronic coronary syndromes, patients with acute coronary syndromes (ACS) are more likely to suffer from long term major adverse cardiac events (MACE). To prevent this, both the American and the European guidelines recommend prolonging dual antiplatelet therapy (DAPT) in this population for at least 12&nbsp;months. However, in patients with certain clinical<a href="https://solaci.org/en/2022/03/21/abbreviated-dapt-in-acs-the-end-of-clopidogrel-monotherapy/" title="Read more" >...</a>

MitraClip Failure: What Should We Do?

Currently, edge-to-edge therapy with MitraClip has demonstrated efficacy and safety for the treatment of patients with degenerative or functional mitral regurgitation&nbsp; who are at high risk for surgery. However, device-related complications are still present—though their frequency is subsiding due to greater experience, 3D doppler echocardiography development, and technological advancements: loss of leaflet insertion (LLI), single<a href="https://solaci.org/en/2022/03/10/mitraclip-failure-what-should-we-do/" title="Read more" >...</a>

Endocarditis infecciosa post TAVI

Infective Endocarditis in TAVR: What’s the Best Treatment?

Infective Endocarditis (IE) rate after TAVR ranges from 0.7% to 3.4%, depending on the different analyses, and is comparable to that after SAVR.&nbsp; Close to 50% of patients treated with surgery received a prosthetic valve; in TAVR, the figure is lower, possibly due to the characteristics of patients (even though it remains unclear).&nbsp; Researchers looked<a href="https://solaci.org/en/2022/03/04/infective-endocarditis-in-tavr-whats-the-best-treatment/" title="Read more" >...</a>

Last Articles in TAVR in solaci.org

We share the latest works in TAVI published on our website. Last Articles in TAVR in solaci.org 01- HYDRA CE | New Models for TAVR Development The&nbsp;Hydra CE&nbsp;has shown favorable one year efficacy for the&nbsp;new transcatheter aortic valve model,&nbsp;with large effective orifice and low transvalvular gradient associated to an acceptable complications rate.&nbsp; With this study,<a href="https://solaci.org/en/2022/02/14/last-articles-in-tavr-in-solaci-org/" title="Read more" >...</a>

Top